T2 Biosystems, Inc.: Nasdaq/NYSE listing notice — T2 Biosystems receives Nasdaq delisting; stock to trade OTC from Feb 12

T2 Biosystems, Inc.

Nasdaq Panel determined to delist T2 Biosystems common stock; trading suspended at open on Feb 12, 2025.
Company violated Bid Price Rule (5550(a)(2)) and Market Value of Listed Securities Rule (5550(b)(2)).
Company will not appeal; expects Nasdaq to file Form 25-NSE with SEC.
Stock to trade under TTOO on OTC Markets starting Feb 12; plans to apply for OTCQX quotation.
No assurance of continued trading liquidity or broker-dealer support on OTC market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 1.0

T2 Biosystems, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5550(b)(2)

Exact text from the filing

February 10, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified T2 Biosystems, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s common stock will be suspended at the open of trading on February 12, 2025. As previously reported, the Company was in violation of the bid price requirement of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and the market value of listed securities requirement in Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with the terms of the previously impo

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-25-024057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.